Discovery of an Anion-Dependent Farnesyltransferase
Inhibitor from a Phenotypic Screen |
| |
Authors: | Marina Bukhtiyarova Erica M. Cook Paula J. Hancock Alan W. Hruza Anthony W. Shaw Gregory C. Adam Richard J. O. Barnard Philip M. McKenna M. Katharine Holloway Ian M. Bell Steve Carroll Ivan Cornella-Taracido Christopher D. Cox Peter S. Kutchukian David A. Powell Corey Strickland B. Wesley Trotter Matthew Tudor Scott Wolkenberg Jing Li David M. Tellers |
| |
Affiliation: | †MRL, Merck & Co., Inc., West Point, Pennsylvania 19486, United States;‡MRL, Merck & Co., Inc., Boston, Massachusetts, 02115, United States;§MRL, Merck & Co., Inc., Kenilworth, New Jersey, 07033, United States |
| |
Abstract: | By employing a phenotypic screen, a set of compounds, exemplified by 1, were identified which potentiate the ability of histone deacetylase inhibitor vorinostat to reverse HIV latency. Proteome enrichment followed by quantitative mass spectrometric analysis employing a modified analogue of 1 as affinity bait identified farnesyl transferase (FTase) as the primary interacting protein in cell lysates. This ligand-FTase binding interaction was confirmed via X-ray crystallography and temperature dependent fluorescence studies, despite 1 lacking structural and binding similarity to known FTase inhibitors. Although multiple lines of evidence established the binding interaction, these ligands exhibited minimal inhibitory activity in a cell-free biochemical FTase inhibition assay. Subsequent modification of the biochemical assay by increasing anion concentration demonstrated FTase inhibitory activity in this novel class. We propose 1 binds together with the anion in the active site to inhibit farnesyl transferase. Implications for phenotypic screening deconvolution and HIV reactivation are discussed. |
| |
Keywords: | HIV latency phenotypicscreen HDAC inhibitor farnesyltransferase inhibitor |
|
|